ImpactU Versión 3.11.2 Última actualización: Interfaz de Usuario: 16/10/2025 Base de Datos: 29/08/2025 Hecho en Colombia
Safety and efficacy of ruxolitinib (RUX) in patients with intermediate-1-risk myelofibrosis (MF) from an open-label, multicenter, single-arm expanded-access study
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY logo search 20th Congress of European-Hematology-Association, Date: 2015/06/11 - 2015/06/14, Location: Vienna: AUSTRIA Publication date: 2015-01 Volume: 100 Pages: 265 - 265 ISSN: 0390-6078, 1592-8721 Publisher: Il Pensiero Scientifico Haematologica SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1-RISK
Tópico:
Myeloproliferative Neoplasms: Diagnosis and Treatment
